Aquestive board member Santo J. Costa resigns; Cochran and Morris assume committee roles

Aquestive Therapeutics, Inc.

Santo J. Costa resigned from board effective Nov 4, 2024 for personal reasons; no disagreement with company.
John S. Cochran appointed Chair of Compensation Committee effective Nov 4, 2024.
Timothy E. Morris added to Compensation Committee; board size reduced from 8 to 7 directors.
Company thanked Costa for his years of service and dedication.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Santo J. Costa

Director

AQST · Aquestive Therapeutics, Inc.

Effective: 2024-11-04
Filed: November 7, 2024, 6:59 PM ET

On November 1, 2024, Santo J. Costa, a member of the Board of Directors of Aquestive Therapeutics, Inc. (the “Company”) and the Chairman of the Compensation Committee thereof (the “Compensation Committee”), notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective November 4, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Santo J. Costa resigned as Director at Aquestive Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On November 1, 2024, Santo J. Costa, a member of the Board of Directors of Aquestive Therapeutics, Inc. (the “Company”) and the Chairman of the Compensation Committee thereof (the “Compensation Committee”), notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective November 4, 2024.

View on SEC.gov

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-046223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.